ConductScience.org, home
hypogonadism
API referenceFor AI assistants

Disease · MONDO_0002146

Comparisons in its trials42

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

1 to 20 of 42

Download this page as JSON
ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
AndroGel 1.62% vs Placebo: Time From Randomization to First Clinical Fracture: Number and Percentage of Participants With an Event91 of 2,60164 of 2,6035,204NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Heart Failure55 of 2,59650 of 2,6025,198NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of All Cause Mortality144 of 2,596148 of 2,6025,198NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Prostate Cancer12 of 2,59611 of 2,6025,198NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Time From Randomization to the First Component Event of Major Adverse Cardiac Event (MACE): Number and Percentage of Participants With an Event182 of 2,596190 of 2,6025,198NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Acute Urinary Retention20 of 2,59616 of 2,6025,198NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Pharmacologic Treatment for Lower Urinary Tract Symptoms101 of 2,59687 of 2,6025,198NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Peripheral Arterial Revascularization30 of 2,59633 of 2,6025,198NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Invasive Prostate Surgical Procedures for Benign Prostatic Hyperplasia23 of 2,59612 of 2,6025,198NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Incidence of High-Grade Prostate Cancer5 of 2,5963 of 2,6025,198NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Time From Randomization to the First Component Event of CV Safety Endpoint: Number and Percentage of Participants With an Event269 of 2,596264 of 2,6025,198NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Prostate Biopsy16 of 2,59614 of 2,6025,198NCT03518034Trial comparisons
AndroGel 1.62% vs Placebo: Tertiary Endpoint: Incidence Rate of Venous Thromboembolic Events44 of 2,59630 of 2,6025,198NCT03518034Trial comparisons
Testosterone Solution vs Placebo Solution: Number of Participants With Total Serum Testosterone Concentration Within Normal Range at Week 12217 of 29743 of 287584NCT01816295Trial comparisons
TU 750 mg vs TU 1000 mg: serious adverse events38 of 27237 of 252524NCT00467870Trial comparisons
Oral Testosterone Undecanoate (TU) vs Topical Testosterone Gel: deaths from any cause0 of 1610 of 160321NCT01403116Trial comparisons
Oral Testosterone Undecanoate (TU) vs Topical Testosterone Gel: serious adverse events11 of 1616 of 160321NCT01403116Trial comparisons
SOV2012-F1-Treated vs Andro-Gel Treated: deaths from any cause1 of 2140 of 100314NCT03198728Trial comparisons
SOV2012-F1-Treated vs Andro-Gel Treated: serious adverse events9 of 2141 of 100314NCT03198728Trial comparisons
T-Gel 1.62% vs Placebo: serious adverse events5 of 2341 of 40274NCT00433199Trial comparisons

diseases-2026-09-18-0.1.0

Next page

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002146/comparisons

API referenceFor AI assistants